The role of circulating serotonin in the development of chronic obstructive pulmonary disease

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Lau, Way K W ^a   Chan Yeung, Moira M W ^a   Yip, Benjamin H K ^a   Cheung, Amy H K ^a   Ip, Mary S M ^a   Mak, Judith C W ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN;

ADULT; AGE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; SEROTONIN BLOOD LEVEL; SMOKING; AGED; BLOOD; CASE CONTROL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; AGE FACTORS; AGED; CASE-CONTROL STUDIES; HUMANS; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEROTONIN; SMOKING;

EID: 84856512594     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031617     Document Type: Article

References (33)

1. Rabe KF, Beghe B, Luppi F, Fabbri LM, (2007) Update in chronic obstructive pulmonary disease 2006. Am J Respir Crit Care Med 175: 1222-1232.
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163: 1256-1276.
3. Hogg JC, (2004) Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364: 709-721.
4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, et al. (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176: 532-555.
5. Murray CJ, Lopez AD, (1997) Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504.
6. U.S. Census Bureau. International Data Base (IDB). Available: www.census.gov/ipc/prod/wp02/appA.pdf. Accessed 2011 March 30.
7. Chan-Yeung M, Ho AS, Cheung AH, Liu RW, Yee WK, et al. (2007) Determinants of chronic obstructive pulmonary disease in Chinese patients in Hong Kong. Int J Tuberc Lung Dis 11: 502-507.
8. Lee JJ, Chang CK, Liu IM, Chi TC, Yu HJ, et al. (2001) Changes in endogenous monoamines in aged rats. Clin Exp Pharmacol Physiol 28: 285-289.
9. Eddahibi S, Chaouat A, Morrell N, Fadel E, Fuhrman C, et al. (2003) Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 108: 1839-1844.
10. Brenner B, Harney JT, Ahmed BA, Jeffus BC, Unal R, et al. (2007) Plasma serotonin levels and the platelet serotonin transporter. J Neurochem 102: 206-215.
11. Ulrich S, Hersberger M, Fischler M, Nussbaumer-Ochsner Y, Treder U, et al. (2010) Genetic polymorphisms of the serotonin transporter, but not the 2a receptor or nitric oxide synthetase, are associated with pulmonary hypertension in chronic obstructive pulmonary disease. Respiration 79: 288-295.
12. Repapi E, Sayers I, Wain LV, Burton PR, Johnson T, et al. (2010) Genome-wide association study identifies five loci associated with lung function. Nat Genet 42: 36-44.
13. Ishii T, Wakabayashi R, Kurosaki H, Gemma A, Kida K, (2011) Association of serotonin transporter gene variation with smoking, chronic obstructive pulmonary disease, and its depressive symptoms. J Hum Genet 56: 41-46.
14. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, et al. (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61: 344-349.
15. Standardization of Spirometry, 1994 Update (1995) American Thoracic Society. Am J Respir Crit Care Med 152: 1107-1136.
16. Ip MS, Ko FW, Lau AC, Yu WC, Tang KS, et al. (2006) Updated spirometric reference values for adult Chinese in Hong Kong and implications on clinical utilization. Chest 129: 384-392.
17. Herr NR. Mediation with dichotomous outcomes. Available: http://nrherr.bol.ucla.edu/Mediation/logmed.html. Accessed 2011 March 30.
18. Preacher KJ. Calculation for the Sobel test. Available: http://people.ku.edu/~preacher/sobel/sobel.htm. Accessed 2011 March 30.
19. Topsakal R, Kalay N, Gunturk EE, Dogan A, Inanc MT, et al. (2009) The relation between serotonin levels and insufficient blood pressure decrease during night-time in hypertensive patients. Blood Press 18: 367-371.
20. Rausch JL, Fefferman M, Ladisich-Rogers DG, Menard M, (1989) Effect of nicotine on human blood platelet serotonin uptake and efflux. Prog Neuropsychopharmacol Biol Psychiatry 13: 907-916.
21. Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinnes C, et al. (2011) Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 66: 769-774.
22. Mercado CP, Kilic F, (2010) Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol Interv 10: 231-241.
23. Lechin F, van der Dijs B, Orozco B, Lechin M, Lechin AE, (1996) Increased levels of free serotonin in plasma of symptomatic asthmatic patients. Ann Allergy Asthma Immunol 77: 245-253.
24. Sciurba FC, (2004) Physiologic similarities and differences between COPD and asthma. Chest 126: 117S-124S.
25. Ban Y, Watanabe T, Miyazaki A, Nakano Y, Tobe T, et al. (2007) Impact of increased plasma serotonin levels and carotid atherosclerosis on vascular dementia. Atherosclerosis 195: 153-159.
26. Kereveur A, Callebert J, Humbert M, Hervé P, Simonneau G, et al. (2000) High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol 20: 2233-2239.
27. Ortiz J, Artigas F, Gelpi E, (1988) Serotonergic status in human blood. Life Sci 43: 983-990.
28. Kumar AM, Weiss S, Fernandez JB, Cruess D, Eisdorfer C, (1998) Peripheral serotonin levels in women: role of aging and ethnicity. Gerontology 44: 211-216.
29. Herraiz T, Chaparro C, (2005) Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 326: 378-386.
30. Khalil AA, Davies B, Castagnoli N Jr, (2006) Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorg Med Chem 14: 3392-3398.
31. Khalil AA, Steyn S, Castagnoli N Jr, (2000) Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem Res Toxicol 13: 31-35.
32. Mendez-Alvarez E, Soto-Otero R, Sanchez-Sellero I, López-Rivadulla Lamas M, (1997) Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke. Life Sci 60: 1719-1727.
33. Hart CM, Block ER, (1989) Lung serotonin metabolism. Clin Chest Med 10: 59-70.